Dunedin born researcher Dr Bob Anderson has been working on the drug, Nexvax2, at Massachusetts biotech company ImmusanT since 2012.
In 2014, phase one trials in locations including Auckland taught researchers that coeliac symptoms were triggered by T cells rapidly responding to gluten peptides.
It also showed that the immune system could be retrained to ignore gluten peptides by administering repeated doses of Nexvax2.
The phase two study aimed to show that regular doses of the drug could protect against the effects of one-off gluten exposure in coeliac patients doing their best to avoid gluten.
"The goal with Nexvax2 is not to replace the gluten-free diet, but to protect against acute symptoms due to inadvertent gluten exposure, an all too common problem faced by coeliac patients on a frequent basis," he said.
But, Anderson hoped that one day Nexvax2 may go a step further and allow for relaxation of dietary restrictions in people with the disease.
To find out more about taking part in the studies phone 0800 STUDIES in Auckland, 04 801 0002 in Wellington or 0800 141 559 in Havelock North.